Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
Pivotal top-line data readout expected in mid-2023 WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) —…